Short Term Trading Weekend Lounge: 5 - 7th August, page-74

when looking at bios i tend to look more at categories.

category 1 which is my faourite would be devices, tests. eg

NAN probe sterilisation. Expensive and needs to expand product range to other devices which it will,
IPD bioimpedance assessment peeps know my views,
UCM blood pressure assess and breathing stuff,reasonable progress into China but
ATC blood pressure assess. I prefer ucm unit as cheaper,
ALT two products the first which attracted me was the autoburette but this never went anywhere until recent signs of life, also a device for women to tighten their pelvic floors, slow uptake of this. one best avoided imo,
RNO anti-snoring device not convinced.
CMP
UBI which i sold out of due to US issues re the home testing for iron but now is probably not bad value again.
I am sure i have missed some.

category 2 would be the regenerative/ stem cell stuff.
MSB, RGS, CYP, AVH, AHZ , RVA, OCC, PNV. I kind of like all of these except rgs but am not holding any atm.
RVA (bioabsorbable stents) seems a bit expensive but then it has had big insto funding and its progression has been a template of how to do it.
AHZ has good product for heart and valve repairs with other usages ( dura,bladder) but sales traction slow and hampered by vacc side which sucks up money and high expenses . Still the vacc platform could be a real winner.
AVH another good product but agian previous management were a bit of a disaster, still needs sales, FDA approval could still be a year away and I am a little concerned that the proposed way of introducing product will be st cost expensive. ( ie they expect to have one of their experts preseent every time someone new uses it). Still probably my fav for value and will reenter after the cr fallout.
OCC seem to be able to perform wonders for tendons and cartilege but sales fell last quarter and still fairly early stage.
PNV another promising tech. Full thickness skin repair. Think I read somewhere of other uses recently. anyone care to add?

More ramblings tomorrow.